C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass.
| Revenue (Most Recent Fiscal Year) | $35.58M |
| Net Income (Most Recent Fiscal Year) | $-105.32M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.00 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -259.27% |
| Net Margin (Trailing 12 Months) | -259.60% |
| Return on Equity (Trailing 12 Months) | -45.86% |
| Return on Assets (Trailing 12 Months) | -28.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.37 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.52 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 71.01M |
| Free Float | 64.81M |
| Market Capitalization | $119.29M |
| Average Volume (Last 20 Days) | 0.99M |
| Beta (Past 60 Months) | 2.94 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.73% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.81% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |